Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

amgen ltd - blinatumomab - powder for solution for infusion - 38.5microgram

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - emicizumab 150 mg/ml - solution for injection - 150 mg/ml - active: emicizumab 150 mg/ml excipient: arginine aspartic acid histidine poloxamer 188 water for injection - hemlibra is indicated for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in adult and paediatric patients with haemophilia a (congenital factor viii deficiency) with or without factor viii inhibitors.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - emicizumab 150 mg/ml - solution for injection - 150 mg/ml - active: emicizumab 150 mg/ml excipient: arginine aspartic acid histidine poloxamer 188 water for injection - hemlibra is indicated for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in adult and paediatric patients with haemophilia a (congenital factor viii deficiency) with or without factor viii inhibitors.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - emicizumab 150 mg/ml - solution for injection - 150 mg/ml - active: emicizumab 150 mg/ml excipient: arginine aspartic acid histidine poloxamer 188 water for injection - hemlibra is indicated for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in adult and paediatric patients with haemophilia a (congenital factor viii deficiency) with or without factor viii inhibitors.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - emicizumab 30 mg/ml - solution for injection - 30 mg/ml - active: emicizumab 30 mg/ml excipient: arginine aspartic acid histidine poloxamer 188 water for injection - hemlibra is indicated for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in adult and paediatric patients with haemophilia a (congenital factor viii deficiency) with or without factor viii inhibitors.

Malesia - englanti - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

roche (malaysia) sdn. bhd. - emicizumab -

Malesia - englanti - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

roche (malaysia) sdn. bhd. - emicizumab -

Israel - englanti - Ministry of Health

roche pharmaceuticals (israel) ltd - mosunetuzumab - concentrate for solution for infusion - mosunetuzumab 1 mg / 1 ml - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Singapore - englanti - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - teclistamab - injection, solution - teclistamab 10mg/ml

Australia - englanti - Department of Health (Therapeutic Goods Administration)

haemokinesis limited - ct885 - immunohaematology (blood banking) ivds - the stargel10 system provides abo forward and reverse grouping, rh(d) typing, rh phenotyping and kell grouping, antibody screening and identification, direct antiglobulin testing (polyspecific and monospecific) and crossmatching procedures.